Clinical Trial Update: Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction [Phase 4]

View source ↗

Summary

Phase 4 clinical trial updating the effects of empagliflozin on left atrial function in heart failure with preserved or mildly reduced ejection fraction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Mid-range Ejection Fraction
• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Zhijun Sun | Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction | Phase 4 | Status: UNKNOWN